用abemaciclib治疗的乳腺癌患者功能评估的挑战:一个案例报告
André Ferreira1,2, José Brito da Silva3, Maria Teresa Chuva2
1Department of Nephrology, Unidade Local de Saúde Viseu Dão-Lafões, Viseu, PRT.
Cureus
|September 25, 2024
概括
在乳腺癌患者中,abemaciclib可以提高血清肌素和囊素-C,而不会影响真正的功能. 医疗保健提供者应使用替代生物标志物来评估膜过率 (GFR),并避免不必要的治疗中止.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 作为CDK4/6抑制剂的Abemaciclib是激素受体阳性,HER-2-阴性乳腺癌的标准治疗方法.
- 众所周知,abemaciclib会导致血清肌素的升高,这并不反映真正的功能下降.
- 这种肌素升高可能会使接受治疗的癌症患者的功能评估复杂化.
研究的目的:
- 在接受abemaciclib治疗的患者中报告肌素和囊素C升高的病例.
- 强调评估真正的功能的重要性,尽管生物标志物升高.
- 讨论继续癌症治疗的影响.
主要方法:
- 一个74岁的女性患者接受abemaciclib.lib的病例报告.
- 监测血清中的肌素和囊素C水平.
- 评估使用脏扫描测量膜过率 (GFR).
主要成果:
- 患者在治疗abemaciclib期间表现出血清肌素和囊素-C的升高.
- 脏扫描证实,测量的GFR没有下降,表明脏功能得到保护.
- 这一发现允许继续治疗abemaciclib.
结论:
- 阿贝马西克利布可以增加血清肌素和囊素-C,而不会损害实际的功能.
- 医疗保健提供者必须警abemaciclib对肌素的特定影响,并考虑替代GFR评估方法.
- 需要进一步的研究,以澄清在接受abemaciclib.com的患者中囊-C的效用.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
61
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
61
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Renal Failure: Dose Adjustments
68
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


